This search looks for keywords in all of the website’s content. Search tips
Filter by
- Agenda(1913)
- Annex to CHMP highlights(367)
- Annual Report(91)
- Application withdrawal assessment report(276)
- Committee meeting report(882)
- COVID-19 vaccine safety update(71)
- Direct healthcare professional communication(122)
- EPAR - All authorised presentations(1978)
- EPAR - Amended Product Information(1)
- EPAR - Assessment report - Variation(2706)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(140)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(42)
- EPAR - Conditions imposed on member states for safe and effective use(112)
- EPAR - Full risk management plan(0)
- EPAR - Overview(1974)
- EPAR - Paediatric investigation plan compliance statement(88)
- EPAR - Procedural steps taken and scientific information after authorisation(1887)
- EPAR - Procedural steps taken before authorisation(484)
- EPAR - Product Information(1974)
- EPAR - Public assessment report(1549)
- EPAR - Risk-management-plan summary(1139)
- EPAR - Scientific conclusion(1358)
- EPAR - Scientific Discussion(504)
- EPAR - Scientific Discussion - Variation(188)
- EPAR - Steps taken after authorisation when a cutoff date has been used(170)
- Herbal - Call for data(293)
- Herbal - Herbal monograph(118)
- Herbal - HMPC assessment report(476)
- Herbal - HMPC opinion on a European Union herbal monograph(247)
- Herbal - List of references supporting the assessment report(462)
- Herbal - Overview of comments received during consultation(164)
- Herbal - Summary of assessment report for the public(120)
- Herbal – European Union herbal monograph(330)
- Herbal – European Union list entry(19)
- Leaflet(71)
- Maximum Residue Limits - Divergent opinion(2)
- Maximum Residue Limits - Opinion(88)
- Maximum Residue Limits - Report(803)
- Maximum Residue Limits - Summary of opinion(14)
- Medicine QA(456)
- Medicines under additional monitoring(22)
- Minutes(1249)
- Newsletter(299)
- Opinion outside EU - All presentations(14)
- Opinion outside EU - Assessment report - Variation(9)
- Opinion outside EU - Medicine questions and answers(1)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(11)
- Opinion outside EU - Procedural steps taken before opinion(3)
- Opinion outside EU - Product information(15)
- Opinion outside EU - Public assessment report(12)
- Opinion outside EU - Risk-management-plan summary(11)
- Opinion outside EU - Scientific discussion(4)
- Opinion outside EU - Summary for the public(15)
- Opinion outside EU - Summary of opinion(3)
- Opinion outside EU - Summary of opinion - Initial authorisation(9)
- Opinion outside EU - Withdrawal assessment report(1)
- Orphan designation(2420)
- Orphan review(106)
- Other(4060)
- Overview of comments(330)
- Parallel distribution(1)
- Periodic safety update single assessment(2760)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(109)
- PIP - Paediatric-investigation-plan summary(93)
- PIP decision(5478)
- Position statement(29)
- PRAC recommendation on signal(164)
- Press Release(1708)
- Procurement(73)
- Public Statement(485)
- Recommendation on medication errors(26)
- Recruitment(38)
- Referrals document(2773)
- Regulatory and procedural guideline(723)
- Report(1619)
- Scientific guideline(2464)
- Standard Operating Procedure - SOP(129)
- Summary of opinion(1224)
- Summary of opinion - Initial authorisation(1674)
- Supply shortage(58)
- Template or form(480)
- Withdrawal letter(290)
- Work Instruction - WIN(61)
- Work programme(151)
- (-)Presentation(5305)
- Advanced therapies(208)
- Antimicrobial resistance(26)
- Biologicals(34)
- Biosimilars(45)
- Brexit(54)
- Careers(0)
- Clinical trials(161)
- Compassionate use(1)
- Compliance and inspections(87)
- Corporate(41)
- COVID-19(41)
- Data on medicines(237)
- Early access(69)
- Fees(0)
- Generic and hybrid medicines(49)
- Governance(11)
- Innovation(170)
- Maximum residue limit(6)
- Medication error(8)
- Medicines(1217)
- Medicines for use outside the EU(0)
- Medicine shortages(7)
- Mpox(0)
- Paediatrics(815)
- Parallel distribution(1)
- Pharmacovigilance(276)
- Procurement(0)
- Product information(281)
- Quality of medicines(10)
- Rare diseases(633)
- Referrals(6)
- Regulatory and procedural guidance(134)
- Research and development(51)
- Scientific advice(38)
- Scientific guidelines(13)
- SME(62)
- Vaccines(39)
- Veterinary limited markets(5)
Search results (5305)
Presentation - Clinical development of psychedelics for psychiatric disorders (N. Hefting, G. Goodwin)
English (EN) (214.59 KB - PDF)
Presentation - Information and Q&A session on updated CAPs in web-based eAF
English (EN) (1.08 MB - PDF)
Presentation - Clinical Trial Information System (CTIS) - Bitesize talk - How to submit a transitional trial in CTIS
English (EN) (391 KB - PDF)
Presentation - Product Management Service (PMS) Info-Day
English (EN) (6.86 MB - PDF)
Presentation - What can patient and public involvement in research contribute to safe and effective use (I. Dziobek)
English (EN) (901.99 KB - PDF)
Presentation - Clinical experience learned from approved esketamine and potential implications for psychedelics (P. Gorwood)
English (EN) (763.51 KB - PDF)
Presentation - Psychedelic treatments; questions from research and clinical implementation (R. Schoevers)
English (EN) (2.71 MB - PDF)
Presentation - Set and setting research potential implications for future approval (M. Beckman)
English (EN) (590.98 KB - PDF)
Presentation - Drawing from ongoing trials and existing clinical experience (E. Bałkowiec-Iskra)
English (EN) (1.13 MB - PDF)
Presentation - Identification of methodological issues and how to overcome them (G. Knudsen)
English (EN) (1.41 MB - PDF)